6 recruiting, 1 active not recruiting, 1 completed, 1 not yet recruiting. 5 Phase 2, 4 Phase 3, 2 Phase 1, 1 Early Phase 1, 1 Not applicable.
Follow sugemalimab: new trials by email Literature Review of sugemalimab trials Research Report on sugemalimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma Sugemalimab, Placebo, Pegaspargase - Extranodal NK/T-cell Lymphoma | Phase 3 | Not yet recruiting | CStone Pharmaceuticals | 150 | 2027-06-01 | 2026-05-27 |
| Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC Sugemalimab and Chemotherapy, Nab-paclitaxel, Cisplatin - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 140 | 2026-07-01 | 2026-07-17 |
| A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC Cadonilimab (AK104), Sugemalimab - NSCLC (Non-small Cell Lung Cancer) | Phase 3 | Recruiting | Akeso | 560 | 2024-11-12 | 2025-03-12 |
| Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC Low-dose radiotherapy, Etoposide, Cisplatin - Lung Cancer, Extensive-stage Small-cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Sichuan University | 45 | 2024-04-18 | 2026-05-05 |
| Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC Sugemalimab and Chemotherapy - NSCLC | Not applicable | Recruiting | Peking Union Medical College | 150 | 2023-10-10 | 2025-11-25 |
| Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy radiotherapy, Platinum-Based Drug, Immunotherapy - Non-small Cell Lung Cancer Stage III | Phase 3 | Unknown | Zhejiang Cancer Hospital | 105 | 2023-09-15 | 2023-09-13 |
| Safety and Efficacy of NK510 to Treat NSCLC NK510, Tislelizumab，atezolizumab or sugemalimab, systemic therapy as selected by the investigator - NSCLC | Early Phase 1 | Recruiting | Base Therapeutics (Shanghai) Co., Ltd. | 12 | 2023-07-01 | 2026-09-09 |
| Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT Sugemalimab, Placebo - Limited Stage Small Cell Lung Cancer | Phase 2 / Phase 3 | Recruiting | Sun Yat-sen University | 346 | 2023-07-01 | 2023-08-07 |
| A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC Sugemalimab and Chemotherapy - Carcinoma, Non-Small-Cell Lung | Phase 2 | Recruiting | Hunan Cancer Hospital | 41 | 2023-06-14 | 2023-07-11 |
| A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg, Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg, Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | CStone Pharmaceuticals | 26 | 2019-12-16 | 2023-02-06 |
| An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL) sugemalimab - Extranodal NK/T-cell Lymphoma | No longer available | EQRx International, Inc. | 2023-03-27 |
Carcinoma, Non-Small-Cell Lung (3) · Lymphoma, Extranodal NK-T-Cell (2) · Carcinoma, Hepatocellular (1) · Esophageal Squamous Cell Carcinoma (1) · Lung Neoplasms (1) · Neoplasm, Residual (1) · Pleural Effusion, Malignant (1) · Radiation Pneumonitis (1) · Recurrence (1) · Small Cell Lung Carcinoma (1)
CStone Pharmaceuticals (2) · Akeso (1) · Base Therapeutics (Shanghai) Co., Ltd. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · EQRx International, Inc. (1) · Hunan Cancer Hospital (1) · Peking Union Medical College (1) · Sichuan University (1) · Sun Yat-sen University (1) · Zhejiang Cancer Hospital (1)
China (8) · United States (1)
Huai Liu, MD (1) · Hui Wang, MD (1) · Jinming Yu, MD (1) · Li Zhang, MD (1) · Qinzhou Qi (1) · Tangfeng Lv, PhD (1) · Xu Yujin, PhD (1) · Yan Huang, MD (1) · You Lu, MD (1)